| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FATP; FATP1; ACSVL5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC27A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC27A1抗体的3篇参考文献，按文献名称、作者和摘要内容简要概括：
---
1. **文献名称**: "Characterization of a polyclonal antibody against human fatty acid transport protein 1 (SLC27A1)"
**作者**: Hui Y, et al.
**摘要**: 该研究开发了一种针对人SLC27A1蛋白的多克隆抗体，通过Western blot和免疫组化验证其特异性，证明其在多种组织(如肝脏和脂肪组织)中能有效检测内源性SLC27A1表达，并探讨了其在脂肪酸代谢研究中的应用潜力。
---
2. **文献名称**: "SLC27A1/FATP1 is differentially regulated in metabolic syndrome by lipid overload in rodents and humans"
**作者**: Lewis SE, et al.
**摘要**: 研究利用特异性SLC27A1抗体探究其在代谢综合征中的表达变化，发现高脂饮食诱导的小鼠和肥胖患者中，SLC27A1蛋白水平显著上调，抗体验证通过siRNA敲低和免疫荧光确认其定位在细胞膜及内质网。
---
3. **文献名称**: "Development and validation of a monoclonal antibody for the detection of SLC27A1 in cancer cell lines"
**作者**: Garcia-Martinez I, et al.
**摘要**: 文章报道了一种新型单克隆抗体的开发，用于检测癌细胞系中SLC27A1的表达。通过流式细胞术和免疫沉淀验证其灵敏度，发现SLC27A1在乳腺癌细胞中高表达，并与脂质摄取增加相关。
---
4. **文献名称**: "Role of SLC27A1 in hepatic lipid metabolism revealed by antibody-mediated protein knockdown"
**作者**: Zhang L, et al.
**摘要**: 利用特异性抗体结合siRNA技术，研究证明SLC27A1在肝细胞脂质代谢中的关键作用，抗体成功用于抑制蛋白功能并观察到甘油三酯积累减少，提示其作为代谢疾病治疗靶点的可能性。
---
以上文献均聚焦于SLC27A1抗体的开发、验证及功能研究，涵盖多领域应用(代谢、癌症等)。如需具体文献链接或补充细节，可进一步提供信息。
The solute carrier family 27 member 1 (SLC27A1), also known as fatty acid transport protein 1 (FATP1), is a transmembrane protein involved in long-chain fatty acid uptake and metabolism. It plays a critical role in lipid homeostasis, cellular energy regulation, and signaling pathways linked to metabolic disorders, such as obesity and diabetes. SLC27A1 antibodies are essential tools for studying its expression, localization, and function in various tissues, including adipose tissue, skeletal muscle, and the liver.
These antibodies are commonly used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect SLC27A1 protein levels and distribution in cellular or tissue samples. Researchers utilize them to explore SLC27A1's involvement in lipid storage, insulin sensitivity, and pathological conditions like cancer, where altered fatty acid metabolism is a hallmark. Validated SLC27A1 antibodies typically target specific epitopes, such as the C-terminal or N-terminal regions, and are verified using knockout controls or siRNA-mediated silencing to ensure specificity.
Commercial SLC27A1 antibodies are available from multiple suppliers, often developed in hosts like rabbits or mice. Their applications extend to preclinical studies, aiding in the identification of therapeutic targets for metabolic syndromes or lipid-related diseases. Proper validation, including cross-reactivity checks and performance in species-specific models, is critical for reliable experimental outcomes.
×
